The startup provides personalized T-cell therapy that utilizes the unique specificity of each patient's T-cells to target the molecular profile of their cancer. This approach enables healthcare providers to deliver tailored and rapid treatments for various cancer types, improving patient outcomes through individualized therapy.
Funding
$55.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer patients do not respond to existing therapies, and even when initial responses occur, relapse is common due to the tumor's ability to evade immune detection. Current cancer treatments often lack the specificity needed to target cancer cells effectively, leading to significant off-target toxicities and limiting their overall efficacy.
Solution
BlueSphere Bio is developing novel T-cell receptor (TCR)-based therapies designed to target a wide range of hematologic malignancies, solid tumors, and rare diseases. The company's TCXpress™ platform enables rapid and efficient TCR discovery, capture, expression, and functional screening, allowing for the creation of extensive TCR libraries. This high-throughput approach facilitates the identification of clinically relevant TCRs that can be used to develop adoptive cell therapies with improved specificity and efficacy. BlueSphere Bio's NEOXpress platform works in concert with TCXpress to screen tumor-resident TCRs for reactivity to identified neoantigens, further enhancing the precision and personalization of their therapies.
Target Audience
The primary target audience includes patients with hematologic malignancies, solid tumors, and rare diseases who are seeking more effective and personalized treatment options, as well as clinicians and researchers in the field of oncology and immunology.
Features
- TCXpress™ platform: High-throughput TCR capture, expression, and functional screening
- Rapid TCR identification: Processes thousands of single T cells directly into functionally expressed TCRs within days
- Intact TCR isolation: TCRα and TCRβ chains are isolated intact and together for accurate functional screening
- Analytical sequencing: Intact TCRs are sequenced analytically as needed, saving on up-front costs and time
- NEOXpress platform: Screens tumor-resident TCRs for reactivity to identified neoantigens
- Multiplexed screening: Rapidly screens and tests the function of thousands of TCRs to find those specific to key neoantigens
- Clinical programs: Focus on hematologic malignancies, non-oncology rare diseases, and solid tumors